These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 2458390)

  • 1. In vitro mutagenesis of HLA-B27. Substitution of an unpaired cysteine residue in the alpha 1 domain causes loss of antibody-defined epitopes.
    Taurog JD; el-Zaatari FA
    J Clin Invest; 1988 Sep; 82(3):987-92. PubMed ID: 2458390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro mutagenesis of HLA-B27. Amino acid substitutions at position 67 disrupt anti-B27 monoclonal antibody binding in direct relation to the size of the substituted side chain.
    el-Zaatari FA; Sams KC; Taurog JD
    J Immunol; 1990 Feb; 144(4):1512-7. PubMed ID: 1689355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro mutagenesis of HLA-B27: single and multiple amino acid substitutions at consensus B27 sites identify distinct monoclonal antibody-defined epitopes.
    el-Zaatari FA; Taurog JD
    Hum Immunol; 1992 Apr; 33(4):243-8. PubMed ID: 1379218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epitope mapping of HLA-B27 and HLA-B7 antigens by using intradomain recombinants.
    Toubert A; Raffoux C; Boretto J; Sire J; Sodoyer R; Thurau SR; Amor B; Colombani J; Lemonnier FA; Jordan BR
    J Immunol; 1988 Oct; 141(7):2503-9. PubMed ID: 2459214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification by site-directed mutagenesis of amino acid residues contributing to serologic and CTL-defined epitope differences between HLA-A2.1 and HLA-A2.3.
    Hogan KT; Clayberger C; Bernhard EJ; Walk SF; Ridge JP; Parham P; Krensky AM; Engelhard VH
    J Immunol; 1988 Oct; 141(7):2519-25. PubMed ID: 2459215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of polymorphism between HLA-B27 genomic exon sequences isolated from normal donors and ankylosing spondylitis patients.
    Coppin HL; McDevitt HO
    J Immunol; 1986 Oct; 137(7):2168-72. PubMed ID: 3489755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Status of an unpaired thiol group on the HLA-B27 epitope.
    McLean L; Perrett D; Winrow VR; Archer JR
    Clin Exp Immunol; 1989 Sep; 77(3):417-21. PubMed ID: 2478324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organization, sequence and expression of the HLA-B27 gene: a molecular approach to analyze HLA and disease associations.
    Weiss EH; Kuon W; Dörner C; Lang M; Riethmüller G
    Immunobiology; 1985 Dec; 170(5):367-80. PubMed ID: 3912316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular analysis of the variant alloantigen HLA-B27d (HLA-B*2703) identifies a unique single amino acid substitution.
    Choo SY; St John T; Orr HT; Hansen JA
    Hum Immunol; 1988 Mar; 21(3):209-19. PubMed ID: 3286582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of serologic recognition sites in the human HLA-A2 molecule.
    Santos-Aguado J; Barbosa JA; Biro PA; Strominger JL
    J Immunol; 1988 Oct; 141(8):2811-8. PubMed ID: 2459229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The solvent-inaccessible Cys67 residue of HLA-B27 contributes to T cell recognition of HLA-B27/peptide complexes.
    Appel H; Kuon W; Kuhne M; Hülsmeyer M; Kollnberger S; Kuhlmann S; Weiss E; Zeitz M; Wucherpfennig K; Bowness P; Sieper J
    J Immunol; 2004 Dec; 173(11):6564-73. PubMed ID: 15557146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association with beta 2-microglobulin controls the expression of transfected human class I genes.
    Rein RS; Seemann GH; Neefjes JJ; Hochstenbach FM; Stam NJ; Ploegh HL
    J Immunol; 1987 Feb; 138(4):1178-83. PubMed ID: 3543123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure.
    Allen RL; O'Callaghan CA; McMichael AJ; Bowness P
    J Immunol; 1999 May; 162(9):5045-8. PubMed ID: 10227970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope mapping of human monoclonal antibodies to HLA-B27 by using natural and mutated antigenic variants.
    Weyl D; Hansen T; Deschamps Y; Hannestad K; Toubert A
    Hum Immunol; 1991 Aug; 31(4):271-6. PubMed ID: 1717416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-reactive T cell clones from unrelated individuals reveal similarities in peptide presentation between HLA-B27 and HLA-DR2.
    López D; Barber DF; Villadangos JA; López de Castro JA
    J Immunol; 1993 Apr; 150(7):2675-86. PubMed ID: 7681078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the substitution of critical residues on the allorecognition of HLA-B27.
    Ozen S; Clayberger C; Krensky AM; Benjamin R
    Clin Exp Rheumatol; 1992; 10(6):583-7. PubMed ID: 1282853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary structure of papain-solubilized human histocompatibility antigen HLA-B27.
    Ezquerra A; Bragado R; Vega MA; Strominger JL; Woody J; López de Castro JA
    Biochemistry; 1985 Mar; 24(7):1733-41. PubMed ID: 2408663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid genes between HLA-A2 and HLA-A3 constructed by in vivo recombination allow mapping of HLA-A2 and HLA-A3 polymorphic antigenic determinants.
    Sire J; Chimini G; Boretto J; Toubert A; Kahn-Perles B; Layet C; Sodoyer R; Lemonnier F; Jordan B
    J Immunol; 1988 Apr; 140(7):2422-30. PubMed ID: 2450922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a free sulphydryl group on expression of HLA-B27 specificity.
    Archer JR; Whelan MA; Badakere SS; McLean IL; Archer IV; Winrow VR
    Scand J Rheumatol Suppl; 1990; 87():44-50. PubMed ID: 1701920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ME1 epitope of HLA-B27 confers class I-mediated modulation of gram-negative bacterial invasion.
    Kapasi K; Inman RD
    J Immunol; 1994 Jul; 153(2):833-40. PubMed ID: 7517424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.